Specialized Cancer Center Support Grant

专门癌症中心支持补助金

• 批准号: 9070302
• 负责人: SCOTT M LIPPMAN
• 金额: $ 381.23万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 1996
• 资助国家: 美国
• 起止时间: 1996-07-01 至 2019-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9070302
• 关键词: Academia; Basic Science; Bioinformatics; Biological Sciences; Biometry; Biotechnology; Cancer Biology; Cancer Burden; Cancer Center; Cancer Center Support Grant; Caring; Clinical; Clinical Sciences; Collaborations; Comprehensive Cancer Center; Detection; Diet; Direct Costs; Division of Basic Sciences; Environment; Flow Cytometry; Funding; Genomics; Goals; Hematologic Neoplasms; Industry; Institutes; Instruction; Investments; Journals; Malignant Neoplasms; Medicine; Microscopy; Mission; Organizational Change; Paper; Peer Review; Physical activity; Physicians; Population Sciences; Private Sector; Public Sector; Publishing; Recording of previous events; Reporting; Research; Research Institute; Research Personnel; Resource Sharing; Resources; Science; Scientist; Signal Transduction; Site; Solid Neoplasm; Source; Technology; Therapeutic; Tissues; Transgenic Mice; Translations; Universities; Vision; base; biobank; cancer genome; cancer health disparity; cancer prevention; cancer therapy; design; innovation; interdisciplinary collaboration; member; programs

The UC San Diego (UCSD) Moores Cancer Center (MCC) has a rich history as a matrix, NCI-designated comprehensive cancer center, now with 239 members from 28 UCSD departments. Peer-reviewed MCC funding is $118.3 million (direct costs), of which $33.2 million is from the NCI. An additional $15.6 million from non-peer-reviewed sources results in total direct-cost funding of $133.9 million. We have published over 4000 cancer-focused papers in the funding period (20% inter- or intraprogrammatic; 10% in journals with an impact factor >15). MCC is surrounded by several other major life-science research institutes and 489 biotechnology companies in San Diego/La Jolla, the 2nd largest life-sciences cluster in the US. MCC is the only NCI-designated comprehensive cancer center in this region. MCC leverages this advantage to save lives by transforming cancer prevention, detection, and care (mission) and to make personalized cancer medicine a reality (vision). This is our first renewal application as a consortium center with partner San Diego State University (SDSU), thus formalizing long-standing, productive collaborations between MCC and SDSU. As designed, the MCC building 1) stimulates interdisciplinary collaboration between physicians and scientists in the Center's Divisions of Basic Science, Clinical Science, and Population Science, 2) assembles the extensive NCI-supported Shared Resources in a common, accessible site, and 3) acts as an academia-industry hub for translational cancer researchers within the public and private sectors of San Diego. The vast majority of members are in the MCC building or on the UCSD campus; others are in nearby La Jolla institutes. This application reports on six Research Programs: Cancer Biology and Signaling, Cancer Genomes and Networks, Hematologic Malignancies, Solid Tumor Therapeutics, Cancer Prevention, and Reducing Cancer Disparities. We also propose seven Shared Resources: Biorepository and Tissue Technology, Biostatistics, Genomics and Bioinformatics, Microscopy, Flow Cytometry, Transgenic Mouse, Diet and Physical Activity. All Programs and Resources reflect the scientific strengths and goals of the MCC. MCC is poised to leverage its exceptional basic and population sciences and San Diego-wide collaborations (academic and private-sector) in developing innovative science-based cancer prevention and treatment. This application summarizes our investments, recruitments, collaborations, organizational changes, plans, and progress toward this goal.

加州大学圣地亚哥分校（UCSD）摩尔斯癌症中心（MCC）具有悠久的矩阵，NCI指定 综合癌症中心，目前有28个UCSD部门的239名成员。同行评审的MCC 资金为1.183亿美元（直接费用），其中3320万美元来自NCI。另外1560万美元 从未经审查的来源中，直接成本的总成本为1.39亿美元。我们已经发表了 在资金期间，以癌症为中心的4000篇论文（20％的跨图或脑内图；在具有的期刊中为10％ 影响因子> 15）。 MCC周围有其他几个主要的生活科学研究机构和489 圣地亚哥/拉霍亚的生物技术公司是美国第二大生命界的集群。 MCC是该地区唯一一个NCI指定的综合癌症中心。 MCC利用这一点 通过改变预防癌症，检测和护理（任务）来挽救生命的优势 个性化癌症医学是一种现实（视觉）。这是我们作为财团中心的第一个续签应用 与合作伙伴圣地亚哥州立大学（SDSU），从而正式进行了长期的，富有成效的合作 在MCC和SDSU之间。按照设计，MCC大楼1）刺激跨学科的合作 中心基础科学，临床科学和科学家之间的医生和科学家之间 人口科学，2）组装大量的NCI支持的共享资源 站点，3）作为公众转化癌症研究人员的学术界枢纽 圣地亚哥的私营部门。绝大多数成员在MCC大楼或UCSD中 校园;其他人在附近的拉霍亚研究所。该申请报告了六个研究计划：癌症 生物学和信号传导，癌症基因组和网络，血液系统恶性肿瘤，实体瘤 治疗剂，预防癌症和减少癌症差异。我们还建议共享七个 资源：生物座和组织技术，生物统计学，基因组学和生物信息学，显微镜， 流式细胞仪，转基因小鼠，饮食和体育活动。所有程序和资源反映了 MCC的科学优势和目标。 MCC准备利用其杰出的基础和人口科学以及圣地亚哥的范围 合作（学术和私营部门）在开发创新的基于科学的癌症预防和 治疗。该应用程序总结了我们的投资，招聘，合作，组织 改变，计划和进步朝着这个目标。